ÂÜÀòÂÒÂ×

Miranda Toledano is a seasoned executive in the biotechnology and pharmaceutical sectors, currently serving as the Chief Executive Officer and Board Member at Entera Bio Ltd. since September 2018. Under Miranda's leadership, Entera Bio is advancing oral peptide therapies aimed at unmet medical needs and plans to enter clinical phases for several programs by 2025. Additionally, Miranda holds board positions at Journey Medical Corporation and TRIGR Therapeutics Inc., where oversight of critical financial and operational strategies took place. Previous roles include Head of Healthcare Investment Banking at B. Riley Financial, Vice President at Royalty Pharma focused on therapeutic royalty acquisitions, and Head of the Life Science Corporate Finance Group at Ernst & Young (Israel). Miranda possesses an MBA in Finance from NYU Stern School of Business and a BA in Economics from Tufts University.